Research

Zolgensma® Data Shows Rapid, Significant, Clinically Meaningful Benefit in SMA, Including Prolonged Event-free Survival, Motor Milestone Achievement and Durability, Now Up to 5 Years Post-dosing

AveXis, a Novartis company, announced a one-time infusion of Zolgensma® (onasemnogene abeparvovec-xioi) showed rapid, significant, and clinically meaningful therapeutic benefit in patients with spinal muscular atrophy (SMA) across a range of studies, including ...

2020-03-24T16:31:56-05:00March 24th, 2020|Front Page News, Research|

AveXis Presents AVXS-101 Intrathecal Data Demonstrating Remarkable Increases in Hammersmith Functional Motor Scale-Expanded (HFMSE) Scores and a Consistent Clinically Meaningful Response in Older Patients with SMA Type 2

AveXis, a Novartis company, announced that new data from the Phase 1/2 STRONG study demonstrated a one-time intrathecal (IT) administration of AVXS-101 in patients ≥2 years and <5 years of age with spinal ...

2020-03-24T14:23:22-05:00March 24th, 2020|Front Page News, Research|